REG - Aptamer Group PLC - New contract with top 10 pharma

AptamerAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251013:nRSM0761Da&default-theme=true

RNS Number : 0761D  Aptamer Group PLC  13 October 2025

 

 

13 October 2025

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

New contract with top 10 pharma

£112,000 contract builds revenue visibility and reinforces Optimer® momentum

 

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic
binders for the life sciences industry, today announces a new fee-for-service
development contract valued at £112,000 with a top 10 global pharmaceutical
company.

 

This agreement represents success-based repeat business with an existing
partner, focusing on the development of Optimer® binders against two protein
targets to support the partner's internal biomarker research. These binders
are required to function in "real-life" biological matrices, such as muscle
lysates and plasma, which are much more challenging than purified buffers used
in standard laboratory tests. Success here will be a further differentiation
of Optimer® from traditional antibodies.

 

The project follows a staged process, with potential for additional
fee-for-service work for subsequent ELISA development. This builds on the
Group's recent success in delivering validated Optimer® binder pairs for a
top 5 pharma partner. Aptamer retains ownership supporting future licensing
and royalty opportunities.

 

This contract builds on the strong commercial progress outlined in recent
updates, including the £360,000 radiopharmaceutical contract announced on 8
October 2025 and the £315,000 in smaller contract wins in Q1. This latest
agreement marks the fifth significant contract in FY26 and further diversifies
the Group's revenue streams, while underscoring the growing adoption of the
Optimer® platform.

 

The new contract adds to the existing visibility of £1.03 million in contract
value for FY26, bringing the total to approximately £1.14 million, with more
than two-thirds of the year remaining. The Group has a robust fee-for-service
pipeline of £3.3 million, after adjusting for the closure of this deal, which
includes approximately £1.0 million in late-stage discussion. These
developments position the Group for continued commercial advancement, subject
to project timings and conversions.

 

This measure of commercial performance is not indicative of full-year results,
and the Group is not providing formal guidance for FY26, as contract timings,
project completions and revenue recognition can vary significantly across
quarters due to the nature of the business.

 

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "This
£112,000 contract with a top 10 global pharma for Optimer® binder pair
development against two protein targets is aimed at biomarker research with
functionality in complex matrices. This work paves the way for additional
revenue for ELISA assay development and builds on our proven success with a
top 5 pharma partner in this space.

 

The contract adds to our visibility, and our £3.3 million pipeline continues
to convert, demonstrating the versatility and value of our Optimer® platform.
Our emphasis is on converting the pipeline of opportunities into sustainable
growth with the best potential downstream terms for the Group."

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                            +44 (0) 1904 217 404

 Arron Tolley
 SPARK Advisory Partners Limited - Nominated Adviser          +44 (0) 20 3368 3550

 Andrew Emmott
 Turner Pope Investments (TPI) Limited - Broker               +44 (0) 20 3657 0050

 James Pope / Andrew Thacker
 Northstar Communications                                     +44 (0) 113 730 3896

 Sarah Hollins

 

 

About Aptamer Group plc

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTGPGQAUUPAPGP



            Copyright 2019 Regulatory News Service, all rights reserved